Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 2/2006

01-02-2006 | Original Article

Vesiculated alpha-tocopheryl succinate enhances the anti-tumor effect of dendritic cell vaccines

Authors: Lalitha V. Ramanathapuram, Tobias Hahn, Michael W. Graner, Emmanuel Katsanis, Emmanuel T. Akporiaye

Published in: Cancer Immunology, Immunotherapy | Issue 2/2006

Login to get access

Abstract

Alpha tocopheryl succinate (α-TOS) is a non-toxic vitamin E analog under study for its anti-cancer properties. In an earlier study, we showed that α-TOS, when used in combination with non-matured dendritic cells (nmDC) to treat pre-established tumors, acts as an effective adjuvant. In this study, we have used vesiculated α-TOS (Vα-TOS), a more soluble form of α-TOS that is relevant for clinical use, in combination with dendritic cells to treat pre-established murine tumors. We demonstrate that Vα-TOS kills tumor cells in vitro and inhibits the growth of pre-established murine lung carcinoma (3LLD122) as effectively as α-TOS. The combination of Vα-TOS plus non-matured or TNF-α-matured DC is more effective at inhibiting the growth of established tumors than Vα-TOS alone. We also observed that Vα-TOS induces expression of heat shock proteins in tumor cells and that co-incubation of non-matured DC with lysate derived from Vα-TOS-treated tumor cells leads to DC maturation evidenced by up-regulation of co-stimulatory molecules and secretion of IL-12p70. This study therefore demonstrates the immunomodulatory properties of Vα-TOS that may account for its adjuvant effect when combined with DC vaccines to treat established tumors.
Literature
1.
Anderson K, Lawson KA, Simmons-Menchaca M, Sun L, Sanders BG, Kline K (2004) Alpha-TEA plus cisplatin reduces human cisplatin-resistant ovarian cancer cell tumor burden and metastasis. Exp Biol Med (Maywood) 229:1169–1176
2.
Anderson K, Simmons-Menchaca M, Lawson KA, Atkinson J, Sanders BG, Kline K (2004) Differential response of human ovarian cancer cells to induction of apoptosis by vitamin E Succinate and vitamin E analogue, alpha-TEA. Cancer Res 64:4263–4269PubMedCrossRef
3.
Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, Finberg RW, Koo GC, Calderwood SK (2000) HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 6:435–442CrossRefPubMed
4.
5.
Barnett KT, Fokum FD, Malafa MP (2002) Vitamin E succinate inhibits colon cancer liver metastases. J Surg Res 106:292–298PubMedCrossRef
6.
Basu S, Binder RJ, Ramalingam T, Srivastava PK (2001) CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14:303–313CrossRefPubMed
7.
Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK (2000) Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 12:1539–1546PubMedCrossRef
8.
Basu S, Srivastava PK (2003) Fever-like temperature induces maturation of dendritic cells through induction of hsp90. Int Immunol 15:1053–1061PubMedCrossRef
9.
Bethke K, Staib F, Distler M, Schmitt U, Jonuleit H, Enk AH, Galle PR, Heike M (2002) Different efficiency of heat shock proteins (HSP) to activate human monocytes and dendritic cells: superiority of HSP60. J Immunol 169:6141–6148PubMed
10.
Chen W, Syldath U, Bellmann K, Burkart V, Kolb H (1999) Human 60-kDa heat-shock protein: a danger signal to the innate immune system. J Immunol 162:3212–3219PubMed
11.
Dalen H, Neuzil J (2003) Alpha-tocopheryl succinate sensitises a T lymphoma cell line to TRAIL-induced apoptosis by suppressing NF-kappaB activation. Br J Cancer 88:153–158PubMedCrossRef
12.
Fariss MW, Merson MH, O’Hara TM (1989) Alpha-tocopheryl succinate protects hepatocytes from chemical-induced toxicity under physiological calcium conditions. Toxicol Lett 47:61–75PubMedCrossRef
13.
Feng H, Zeng Y, Graner MW, Katsanis E (2002) Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. Blood 100:4108–4115PubMedCrossRef
14.
Flohe SB, Bruggemann J, Lendemans S, Nikulina M, Meierhoff G, Flohe S, Kolb H (2003) Human heat shock protein 60 induces maturation of dendritic cells versus a Th1-promoting phenotype. J Immunol 170:2340–2248PubMed
15.
Israel K, Yu W, Sanders BG, Kline K (2000) Vitamin E succinate induces apoptosis in human prostate cancer cells: role for Fas in vitamin E succinate-triggered apoptosis. Nutr Cancer 36:90–100CrossRefPubMed
16.
Jin Y, Fuller L, Ciancio G, Burke GW 3rd, Tzakis AG, Ricordi C, Miller J, Esquenzai V (2004) Antigen presentation and immune regulatory capacity of immature and mature-enriched antigen presenting (dendritic) cells derived from human bone marrow. Hum Immunol 65:93–103PubMedCrossRef
17.
Jizomoto H, Kanaoka E, Hirano K (1994) pH-sensitive liposomes composed of tocopherol hemisuccinate and of phosphatidylethanolamine including tocopherol hemisuccinate. Biochim Biophys Acta 1213:343–348PubMed
18.
Kobie JJ, Wu RS, Kurt RA, Lou S, Adelman MK, Whitesell LJ, Ramanathapuram LV, Arteaga CL, Akporiaye ET (2003) Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 63:1860–1864PubMed
19.
Kogure K, Manabe S, Hama S, Tokumura A, Fukuzawa K (2003) Potentiation of anti-cancer effect by intravenous administration of vesiculated alpha-tocopheryl hemisuccinate on mouse melanoma in vivo. Cancer Lett 192:19–24CrossRefPubMed
20.
Lawson KA, Anderson K, Menchaca M, Atkinson J, Sun L, Knight V, Gilbert BE, Conti C, Sanders BG, Kline K (2003) Novel vitamin E analogue decreases syngeneic mouse mammary tumor burden and reduces lung metastasis. Mol Cancer Ther 2:437–444PubMed
21.
Lawson KA, Anderson K, Simmons-Menchaca M, Atkinson J, Sun L, Sanders BG, Kline K (2004) Comparison of vitamin E derivatives alpha-TEA and VES in reduction of mouse mammary tumor burden and metastasis. Exp Biol Med (Maywood) 229:954–963
22.
Liu B, Wu K, Zhao D (2000) Study on vitamin E succinate inducing apoptosis of human gastric carcinoma cell. Wei Sheng Yan Jiu 29:234–236PubMed
23.
Malafa MP, Fokum FD, Mowlavi A, Abusief M, King M (2002) Vitamin E inhibits melanoma growth in mice. Surgery 131:85–91CrossRefPubMed
24.
Malafa MP, Neitzel LT (2000) Vitamin E succinate promotes breast cancer tumor dormancy. J Surg Res 93:163–170CrossRefPubMed
25.
Mosser DD, Morimoto RI (2004) Molecular chaperones and the stress of oncogenesis. Oncogene 23:2907–2918CrossRefPubMed
26.
Neuzil J, Weber T, Gellert N, Weber C (2001) Selective cancer cell killing by alpha-tocopheryl succinate. Br J Cancer 84:87–89CrossRefPubMed
27.
Neuzil J, Weber T, Terman A, Weber C, Brunk UT (2001) Vitamin E analogues as inducers of apoptosis: implications for their potential antineoplastic role. Redox Rep 6:143–151CrossRefPubMed
28.
Prasad KN, Kumar B, Yan XD, Hanson AJ, Cole WC (2003) Alpha-tocopheryl succinate, the most effective form of vitamin E for adjuvant cancer treatment: a review. J Am Coll Nutr 22:108–117PubMed
29.
Ramanathapuram LV, Kobie JJ, Bearss D, Payne CM, Trevor KT, Akporiaye ET (2004) alpha-Tocopheryl succinate sensitizes established tumors to vaccination with nonmatured dendritic cells. Cancer Immunol Immunother 53:580–588CrossRefPubMed
30.
Somersan S, Larsson M, Fonteneau JF, Basu S, Srivastava P, Bhardwaj N (2001) Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J Immunol 167:4844–4852PubMed
31.
Srivastava P (2002) Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20:395–425CrossRefPubMed
32.
Todryk S, Melcher AA, Hardwick N, Linardakis E, Bateman A, Colombo MP, Stoppacciaro A, Vile RG (1999) Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol 163:1398–1408PubMed
33.
Weber T, Lu M, Andera L, Lahm H, Gellert N, Fariss MW, Korinek V, Sattler W, Ucker DS, Terman A, Schroder A, Erl W, Brunk UT, Coffey RJ, Weber C, Neuzil J (2002) Vitamin E succinate is a potent novel antineoplastic agent with high selectivity and cooperativity with tumor necrosis factor-related apoptosis-inducing ligand (Apo2 ligand) in vivo. Clin Cancer Res 8:863–869PubMed
34.
Wu RS, Kobie JJ, Besselsen DG, Fong TC, Mack VD, McEarchern JA, Akporiaye ET (2001) Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma. Cancer Immunol Immunother 50:229–240CrossRefPubMed
35.
Yu W, Sanders BG, Kline K (1997) RRR-alpha-tocopheryl succinate inhibits EL4 thymic lymphoma cell growth by inducing apoptosis and DNA synthesis arrest. Nutr Cancer 27:92–101PubMedCrossRef
36.
Yu W, Simmons-Menchaca M, Gapor A, Sanders BG, Kline K (1999) Induction of apoptosis in human breast cancer cells by tocopherols and tocotrienols. Nutr Cancer 33:26–32PubMed
37.
Zheng H, Dai J, Stoilova D, Li Z (2001) Cell surface targeting of heat shock protein gp96 induces dendritic cell maturation and antitumor immunity. J Immunol 167:6731–6735PubMed
Metadata
Title
Vesiculated alpha-tocopheryl succinate enhances the anti-tumor effect of dendritic cell vaccines
Authors
Lalitha V. Ramanathapuram
Tobias Hahn
Michael W. Graner
Emmanuel Katsanis
Emmanuel T. Akporiaye
Publication date
01-02-2006
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 2/2006
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-005-0016-7

Other articles of this Issue 2/2006

Cancer Immunology, Immunotherapy 2/2006 Go to the issue

Symposium in Writing

Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia?

Original Article

Allogeneic gastric cancer cell-dendritic cell hybrids induce tumor antigen (carcinoembryonic antigen) specific CD8+ T cells

Erratum

Binding parameters of antibodies: pseudo-affinity and other misconceptions

Symposium in Writing

Monoclonal antibody therapy of chronic lymphocytic leukemia

Original Article

Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck

Symposium in Writing

T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits